Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$34.79 USD
+0.51 (1.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $34.77 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$34.79 USD
+0.51 (1.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $34.77 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Zacks News
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
by Zacks Equity Research
Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
by Zacks Equity Research
The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.
Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
by Zacks Equity Research
Corcept's (CORT) pipeline progress has been encouraging with relacorilant currently under evaluation for Cushing's syndrome. The NDA for relacorilant is expected to be filed in the third quarter.
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
by Zacks Equity Research
Corcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating patients with Cushing's syndrome, meets the primary endpoint in a randomized withdrawal phase.
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter 2024 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
by Zacks Equity Research
Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for April 17th
by Zacks Equity Research
BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
Corcept (CORT) Completes Enrollment in Phase II ALS Study
by Zacks Equity Research
The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
by Zacks Equity Research
The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
by Zacks Equity Research
Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
Why Is United Therapeutics (UTHR) Up 8.9% Since Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
by Zacks Equity Research
Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.
Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024
by Zacks Equity Research
Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance.
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
by Zacks Equity Research
Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.
Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva
by Zacks Equity Research
The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines.